What’s Under The Iceberg: GE Healthcare’s Deep Dive Look At Future Of Gene Therapy
Cell and gene therapy represent a transformative advance in drug delivery and outcomes, with implications equally as important to human progress as the digital revolution that began three decades ago.In Vivo speaks with a key player in this evolving field, GE Healthcare’s strategy manager for cell and gene therapy and board member of the Alliance for Regenerative Medicine, Phil Vanek, PhD.
You may also be interested in...
Start-Up Spotlight: Distalmotion Wants To Bring Cost-Effective, Focused Alternative To Robotic Surgery Market
Switzerland-based Distalmotion hopes to make its Dexter robotic surgery the standard of care in procedures that entail precise dissection and suturing and market itself as a more cost-effective alternative to Intuitive Surgical’s da Vinci system.
Viz.ai is making artificial intelligence real and ready with an algorithm-based detection and diagnostics platform that is beating the clinical clock in fighting stroke. The start-up is now focused on positioning its joined-up AI software as standard-setter for broader patient engagement with big pharma on everything from participation in clinical trials to launching the next generation of high-touch specialty medicines.
Rising Leader Christopher Jon Stokes of Eli Lilly explains how some early life lessons in the restorative powers of community has guided a distinctive career path marked by engaging widely, understanding intuitively and listening actively, all in the pursuit of forging productive human connections that strive to “meet the moment” for patients.